Corbus' CRB-913 shows 5% mean weight loss at 12 weeks in Phase 1b trial

By Public Technologies
  • Corbus Pharmaceuticals presented Phase 1b CANYON-1 trial results for its oral obesity drug CRB-913 at ObesityWeek 2026.
  • CRB-913 produced statistically significant, clinically meaningful weight loss across all tested doses, with no plateau observed.
  • Psychiatric adverse events were mostly mild and resolved; no serious or severe psychiatric events were reported.
  • Corbus plans FDA discussions on further development and is evaluating potential combinations with GLP-1 therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9878103) on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk